Global MarketsIMPORTANT
Roche (ROP SW) H1 2026 (CHF): Sales 30.36bln (exp. 30.32bln), Core EPS 10.85 (prev. 11.08 Y/Y), Operating Profit 9.67bln (prev. 10.33bln Y/Y), Net Income 7.33bln (prev. 7.83bln Y/Y).
StockNow breaking-news AI analysis
Roche's H1 2026 sales beat expectations with 5% growth at CER, though CHF appreciation significantly weighed on reported profits. The company maintained its full-year growth and dividend targets.
News detail
CHF appreciation, particularly vs the USD, had an adverse impact of 8ppts on sales and 11ppts on core operating profit and core EPS.Sales Breakdown: Pharmaceutical 23.6bln (prev. 24bln), +6% at CER. Xolair was the major growth driver, with Hemlibra, Ocrevus and Phesgo also significantly contributing. Diagnostics 6.7bln (prev. 7.0bln), +3% at CER.
What do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.